Previous close | 7.00 |
Open | 6.93 |
Bid | 50.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 6.52 - 6.93 |
52-week range | 3.70 - 10.80 |
Volume | |
Avg. volume | 66,849 |
Market cap | 124.647M |
Beta (5Y monthly) | 0.70 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.88 |
Earnings date | 19 Mar 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 10.83 |
MILAN, April 08, 2024--Newron presents existing evenamide study 014/015 data and future clinical development outlook for evenamide at 2024 SIRS Congress in Florence, Italy
MILAN, March 19, 2024--Newron Pharmaceuticals announces 2023 year-end financial results and provides 2024 business outlook.
MILAN, March 15, 2024--Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement